CSNK1A1 and myelodysplastic syndrome: For example, degradation of CK1α is a key event for lenalidomide efficacy in del(5q) MDS [46], while GSPT1 degradation is deemed to account for anti-AML activity of CC-885 and CC-90009 [25, 28].